Anpac Bio's Liquid Biopsy Tests Catch 26+ Early-Stage Cancers in Single Blood Test!

Comprehensive research validity data from 60,000+ cases, and independently-corroborated by world-renowned hospitals and cancer research leaders, demonstrate Anpac Bio's CDA diagnostics consistently detects 26+ cancers -- with a sensitivity and specificity rate range of 75%-90%. And it does so without any harmful side effects in patients; generating far fewer "false positives"; at a cost substantially lower than traditional testing; and generating results within minutes of sample submission.

World-renowned, Second Military Medical University and its affiliated Changhai Hospital (CH) in Shanghai, China, have conducted 4,000+ CDA liquid biopsy tests since 2014. Submitting Lung, Esophageal Cancer, and cancer-free control group blood samples, "blinded" to Anpac Bio, CH concluded CDA is a remarkably accurate, non-invasive test, supporting both early diagnosis, and monitoring treatment effectiveness, prognosis, and recurrence.

"Our preliminarily results indicate that CDA technology has better sensitivity and specificity for early diagnosis, as well as potentially a good tool for treatment assessment for Lung Cancer and Esophageal Cancer than traditional tumor markers," reports Dr. Jun-Jie Wu, Deputy Chief Physician, CH Department of Oncology. "It (CDA) can also play a good role in complementing chest CT (Computerized Axial Tomography) screening for pulmonary nodules. The existing data suggests that CDA technology is a promising technology in the field of diagnosis and treatment assessment of Lung Cancer and cancer of the Esophagus."

Described as "game changing", and receiving the, "Breakthrough Innovation Award", at the World Nobel Prize Laureate Summit; and named, "Most Promising Cancer Screening Company", at the 2017 Global Precision Medicine Industry Awards, Anpac Bio's CDA technology effectively reinvents early cancer screening and detection.

By analyzing simple, standard, blood tests, and applying Anpac Bio's proprietary, multi-level, multi-parameter, diagnostic algorithms, Anpac Bio's CDA technology identifies cancer with measurably-greater accuracy than most current, conventional screening methods.

The Oncology Department of Shanghai Changzheng Hospital (SCH) corroborates these results. Since 2016, SCH has conducted two comprehensive clinical research studies of Anpac Bio's CDA's liquid biopsy technology. Submitting over 500 healthy "control" group; "high-risk" group (those genetically or environmentally pre-disposed to developing cancer); and independently-diagnosed and "confirmed cancer" group blood samples; for CDA analysis. 

According to study director and SCH Deputy Professor Dr. Yuan Sheng Zang: "Initial results indicated that CDA technology has better sensitivity and specificity for early-stage cancer screening than that of traditional tumor markers. The evaluation on the significance of CDA technology in prognosis is ongoing. The existing research data suggest that CDA technology has a good prospect in the field of cancer diagnosis and prognosis."

Pioneering liquid biopsy research (launched in 2008), Anpac Bio is already, fully-commercialized and generating revenue from Fortune 500 corporate, insurance, medical, research, and individual ("over the counter") testing; while most competing "liquid biopsy" research remains in the laboratory and unavailable to the general public (for perhaps years).

Additionally, competing tests generally measure only single/few sample indicators (such as gene mutations that may indicate a patient's increased risk or probability of potentially developing cancer at some point). Anpac Bio's CDA is a "functional biology" test – providing medical professionals important information regarding actual disease signals present in the patient's body at the moment of blood draw.

CDA's independently-confirmed, very early stage cancer and pre-cancerous disease detection's efficiency and accuracy is due to the technology's multi-level and multi-parameter, patented design. With over 200 CDA-related patent applications worldwide (65+ currently issued), CDA's integrated system measures numerous protein, molecular, cellular, and other factors, to identify disease signals. By enhancing signal detection and processing, while reducing "noise", the collected data is subsequently analyzed using Anpac Bio's proprietary algorithms.

The resulting data is then assigned an overall value, called "CDA Value", indicating cancer incidence risk level (the higher the CDA Value, the higher cancer risk). CDA's accuracy and advantages have been verified in previous studies, and presented before respected scientific organizations, such as the American Society of Clinical Oncology (ASCO), the Breast Cancer Symposium, and the World Nobel Prize Laureate Summit.

"Every day, our company hears of other, potential 'liquid biopsy' tests that report 'someday' may be used to catch cancer," states Dr. Chris Yu, Anpac Bio Chief Executive Officer. "Our CDA technology has been extensively tested, verified, and used daily by dozens of Asia's most well-respected and renowned medical institutions. We are also generating equally accurate and positive results in the United States. We're very proud that our CDA devices have advanced well-beyond the laboratory and are processing real tests for real people – saving lives every day. On this 'National Cancer Prevention Month', Anpac Bio and our medical partners want the world to know: 'Someday' is now!"

For more information about Anpac Bio please check: www.AnpacBio.com.

Contact: Drisha Leggitt: 916-206-2553 or [email protected]

SOURCE Anpac Bio-Medical Science Company

Related Links

http://anpacbio.com